Abstract
Original language | English |
---|---|
Pages (from-to) | 207-213 |
Number of pages | 7 |
Journal | Crit. Rev. Oncol. Hematol. |
Volume | 138 |
DOIs | |
Publication status | Published - 2019 |
Keywords
- Breast cancer
- Ductal carcinoma in situ
- Hypofractionation
- Post-mastectomy radiotherapy
- Survey
- estrogen receptor
- Ki 67 antigen
- progesterone receptor
- tamoxifen
- age
- breast radiotherapy
- breast reconstruction
- cancer grading
- human
- hypofractionated radiotherapy
- immunohistochemistry
- intensity modulated radiation therapy
- intraductal carcinoma
- mastectomy
- nipple sparing mastectomy
- postmastectomy radiation therapy
- radiation oncologist
- Review
- skin sparing mastectomy
- surgical margin
- surgical technique
- tomotherapy
- tumor volume
- adjuvant radiotherapy
- breast tumor
- female
- middle aged
- prevention and control
- procedures
- questionnaire
- radiation oncology
- risk factor
- tumor recurrence
- Breast Neoplasms
- Carcinoma, Intraductal, Noninfiltrating
- Dose Fractionation, Radiation
- Female
- Humans
- Mastectomy
- Middle Aged
- Neoplasm Recurrence, Local
- Radiation Oncology
- Radiotherapy, Adjuvant
- Risk Factors
- Surveys and Questionnaires
Fingerprint
Dive into the research topics of 'The Assisi Think Tank Meeting Survey of post-mastectomy radiation therapy in ductal carcinoma in situ: Suggestions for routine practice: Critical Reviews in Oncology/Hematology'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
The Assisi Think Tank Meeting Survey of post-mastectomy radiation therapy in ductal carcinoma in situ: Suggestions for routine practice : Critical Reviews in Oncology/Hematology. / Montero-Luis, A.; Aristei, C.; Meattini, I.; Arenas, M.; Boersma, L.; Bourgier, C.; Coles, C.; Cutuli, B.; Falcinelli, L.; Kaidar-Person, O.; Leonardi, M.C.; Offersen, B.; Marazzi, F.; Rivera, S.; Tagliaferri, L.; Tombolini, V.; Vidali, C.; Valentini, V.; Poortmans, P.
In: Crit. Rev. Oncol. Hematol., Vol. 138, 2019, p. 207-213.Research output: Contribution to journal › Article › peer-review
}
TY - JOUR
T1 - The Assisi Think Tank Meeting Survey of post-mastectomy radiation therapy in ductal carcinoma in situ: Suggestions for routine practice
T2 - Critical Reviews in Oncology/Hematology
AU - Montero-Luis, A.
AU - Aristei, C.
AU - Meattini, I.
AU - Arenas, M.
AU - Boersma, L.
AU - Bourgier, C.
AU - Coles, C.
AU - Cutuli, B.
AU - Falcinelli, L.
AU - Kaidar-Person, O.
AU - Leonardi, M.C.
AU - Offersen, B.
AU - Marazzi, F.
AU - Rivera, S.
AU - Tagliaferri, L.
AU - Tombolini, V.
AU - Vidali, C.
AU - Valentini, V.
AU - Poortmans, P.
N1 - Cited By :1 Export Date: 28 February 2020 CODEN: CCRHE Correspondence Address: Montero-Luis, A.; Radiation Oncology, University Hospital HM Sanchinarro, c/Oña 10, Spain; email: amontero@hmhospitales.com Chemicals/CAS: tamoxifen, 10540-29-1 References: Aristei, C., Kaidar-Person, O., Arenas, M., Coles, C., Offersen, B.V., Bourgier, C., Frezza, G., Poortmans, P.M., The 2016 Assisi Think Tank Meeting on breast cancer: white paper (2016) Breast Cancer Res. Treat., 160 (2), pp. 211-221; Bannani, S., Rouquette, S., Bendavid-Athias, C., Tas, P., Levêque, J., The locoregional recurrence post-mastectomy for ductal carcinoma in situ: incidence and risk factors (2015) Breast, 24 (October (5)), pp. 608-612; Carlson, G.W., Page, A., Johnson, E., Nicholson, K., Styblo, T.M., Wood, W.C., Local recurrence of ductal carcinoma in situ after skin-sparing mastectomy (2007) J. Am. Coll. Surg., 204 (May (5)), pp. 1074-1078. , discussion 1078-80; Chadha, M., Portenoy, J., Boolbol, S.K., Gillego, A., Harrison, L.B., Is there a role for postmastectomy radiation therapy in ductal carcinoma in situ? (2012) Int. J. Surg. Oncol., 2012; Chan, L.W., Rabban, J., Hwang, E.S., Bevan, A., Alvarado, M., Ewing, C., Esserman, L., Fowble, B., Is radiation indicated in patients with ductal carcinoma in situ and close or positive mastectomy margins? (2011) Int. J. Radiat. Oncol. Biol. Phys., 80 (May (1)), pp. 25-30; Childs, S.K., Chen, Y.H., Duggan, M.M., Golshan, M., Pochebit, S., Punglia, R.S., Wong, J.S., Bellon, J.R., Impact of margin status on local recurrence after mastectomy for ductal carcinoma in situ (2013) Int. J. Radiat. Oncol. Biol. Phys., 85 (March (4)), pp. 948-952; Ciervide, R., Dhage, S., Guth, A., Shapiro, R.L., Axelrod, D.M., Roses, D.F., Formenti, S.C., Five year outcome of 145 patients with ductal carcinoma in situ (DCIS) after accelerated breast radiotherapy (2012) Int. J. Radiat. Oncol. Biol. Phys., 83 (June (2)), pp. e159-e164; Clements, K., Dodwell, D., Lawrence, G., Ball, G., Francis, A., Pinder, S., Sawyer, E., Sloane Project Steering Group, Radiotherapy after mastectomy for screen-detected ductal carcinoma in situ (2015) Eur. J. Surg. Oncol., 41 (October (10)), pp. 1406-1410; Cuzick, J., Sestak, I., Pinder, S.E., Ellis, I.O., Forsyth, S., Bundred, N.J., Forbes, J.F., George, W.D., Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial (2011) Lancet Oncol., 12 (January (1)), pp. 21-29; Cuzick, J., Sestak, I., Pinder, S.E., Ellis, I.O., Forsyth, S., Bundred NJ Forbes, J.F., Bishop, H., George, W.D., Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial (2011) Lancet Oncol., 12 (January (1)), pp. 21-29; Donker, M., Litière, S., Werutsky, G., Julien, J.P., Fentiman, I.S., Agresti, R., Rouanet, P., Bijker, N., Breast-conserving treatment with or without radiotherapy in ductal carcinoma in situ: 15-year recurrence rates and outcome after a recurrence, from the EORTC 10853 randomized phase III trial (2013) J. Clin. Oncol., 31 (November (32)), pp. 4054-4059; Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), Correa, C., McGale, P., Taylor, C., Wang, Y., Clarke, M., Davies, C., Darby, S., Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast (2010) J. Natl. Cancer Inst. Monogr., 2010 (41), pp. 162-177; Elshof, L.E., Schaapveld, M., Schmidt, M.K., Rutgers, E.J., van Leeuwen, F.E., Wesseling, J., Subsequent risk of ipsilateral and contralateral invasive breast cancer after treatment for ductal carcinoma in situ: incidence and the effect of radiotherapy in a population-based cohort of 10,090 women (2016) Breast Cancer Res. Treat., 159 (October (3)), pp. 553-563; Fisher, B., Dignam, J., Wolmark, N., Wickerham, D.L., Fisher, E.R., Mamounas, E., Smith, R., Oishi, R.H., Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial (1999) Lancet, 353 (June (9169)), pp. 1993-2000; Fitzsullivan, E., Lari, S.A., Smith, B., Incidence and consequence of close margins in patients with ductal carcinoma-in situ treated with mastectomy: is further therapy warranted? (2013) Ann. Surg. Oncol., 20 (13), pp. 4103-4112; Forbes, J.F., Sestak, I., Howell, A., Bonanni, B., Bundred, N., Levy, C., von Minckwitz, G., IBIS-II investigators, Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomized controlled trial (2016) Lancet, 387 (February (10021)), pp. 866-873; Ganz, P.A., Cecchini, R.S., Julian, T.B., Margolese, R.G., Costantino, J.P., Vallow, L.A., Albain, K.S., Wolmark, N., Patient-reported outcomes with anastrozole versus tamoxifen for postmenopausal patients with ductal carcinoma in situ treated with lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial (2016) Lancet, 387 (February (10021)), pp. 857-865; Giannakeas, V., Sopik, V., Narod, S.A., Association of radiotherapy with survival in women treated for ductal carcinoma in situ with lumpectomy or mastectomy (2018) JAMA Netw. Open, 1 (4); Hathout, L., Hijal, T., Théberge, V., Fortin, B., Vulpe, H., Hogue, J.C., Lambert, C., Yassa, M., Hypofractionated radiation therapy for breast ductal carcinoma in situ (2013) Int. J. Radiat. Oncol. Biol. Phys., 87 (December (5)), pp. 1058-1063; Isfahanian, N., Al-Hajri, T., Marginean, H., Chang, L., Caudrelier, J.M., Hypofractionation is an acceptable alternative to conventional fractionation in the treatment of postlumpectomy ductal carcinoma in situ with radiotherapy (2017) Clin. Breast Cancer, 17 (April (2)), pp. e77-e85; Jensen, M.B., Laenkholm, A.V., Offersen, B.V., Christiansen, P., Kroman, N., Mouridsen, H.T., Ejlertsen, B., The clinical database and implementation of treatment guidelines by the Danish Breast Cancer Cooperative Group in 2007–2016 (2018) Acta Oncol., 57 (1), pp. 13-18; Jones, C.E., Richman, J., Jackson, B.E., Wallace, A.S., Krontiras, H., Urist, M.M., Bland, K.I., Parker, C.C., Treatment patterns for ductal carcinoma in situ with close or positive mastectomy margins (2018) J. Surg. Res., 231 (November), pp. 36-42; Karavites, L.C., Kane, A.K., Zaveri, S., Xu, Y., Helenowski, I., Hansen, N., Bethke, K.P., Khan, S.A., Tamoxifen acceptance and adherence among patients with ductal carcinoma in situ (DCIS) treated in a multidisciplinary setting (2017) Cancer Prev. Res. (Phila.), 10 (July (7)), pp. 389-397; Kelley, L., Silverstein, M., Guerra, L., Analyzing the risk of recurrence after mastectomy for DCIS: a new use for the USC/Van Nuys Prognostic Index (2011) Ann. Surg. Oncol., 18 (February (2)), pp. 459-462; Klein, J., Kong, I., Paszat, L., Close or positive resection margins are not associated with an increased risk of chest wall recurrence in women with DCIS treated by mastectomy: a population-based analysis (2015) SpringerPlus, 4, p. 335. , Published 2015 Jul 10; Lalani, N., Paszat, L., Sutradhar, R., Thiruchelvam, D., Nofech-Mozes, S., Hanna, W., Slodkowska, E., Rakovitch, E., Long-term outcomes of hypofractionation versus conventional radiation therapy after breast-conserving surgery for ductal carcinoma in situ of the breast (2014) Int. J. Radiat. Oncol. Biol. Phys., 90 (December (5)), pp. 1017-1024; Mallon, P.T., McIntosh, S.A., Post mastectomy radiotherapy in breast cancer: a survey of current United Kingdom practice (2012) J. BUON, 17 (April-June (2)), pp. 245-248; Margolese, R.G., Cecchini, R.S., Julian, T.B., Ganz, P.A., Costantino, J.P., Vallow, L.A., Albain, K.S., Wolmark, N., Anastrozole versus tamoxifen in postmenopausal women with ductal carcinoma in situ undergoing lumpectomy plus radiotherapy (NSABP B-35): a randomised, double-blind, phase 3 clinical trial (2016) Lancet, 387 (February (10021)), pp. 849-856; McCormick, B., Randomized trial evaluating radiation following surgical excision for “good risk” DCIS: 12-year report from NRG/ RTOG 9804 2018 ASTRO Annual Meeting Late-breaking Abstract Selection (2019) Int. J. Radiat. Oncol. Biol. Phys., 102 (November (3) (Supplement)); McCormick, B., Winter, K., Hudis, C., Kuerer, H.M., Rakovitch, E., Smith, B.L., Sneige, N., White, J., RTOG 9804: a prospective randomized trial for good-risk ductal carcinoma in situ comparing radiotherapy with observation (2015) J. Clin. Oncol., 33 (March (7)), pp. 709-715; Meattini, I., Lambertini, M., Isacco, D., De Caluwé, A., Kaidar-Person, O., Lorenzo, L.L., Radiation therapy for young women with early breast cancer: current state of the art (2019) Crit. Rev. Oncol. Hematol., p. 137; Montero, A., Sanz, X., Hernanz, R., Cabrera, D., Arenas, M., Bayo, E., Moreno, F., Algara, M., Accelerated hypofractionated breast radiotherapy: FAQs (frequently asked questions) and facts (2014) Breast, 23 (August (4)), pp. 299-309; Pesce, C.E., Liederbach, E., Czechura, T., Winchester, D.J., Yao, K., Changing surgical trends in young patients with early stage breast cancer, 2003 to 2010: a report from the National Cancer Data Base (2014) J. Am. Coll. Surg., 219 (July (1)), pp. 19-28; Rakovitch, E., Nofech-Mozes, S., Hanna, W., Sutradhar, R., Gu, S., Fong, C., Tuck, A., Paszat, L., Omitting radiation therapy after lumpectomy for pure DCIS does not reduce the risk of salvage mastectomy (2018) Breast, 37 (February), pp. 181-186; Rashtian, A., Iganej, S., Amy Liu, I.L., Natarajan, S., Close or positive margins after mastectomy for DCIS: pattern of relapse and potential indications for radiotherapy (2008) Int. J. Radiat. Oncol. Biol. Phys., 72 (November (4)), pp. 1016-1020; Rutter, C.E., Park, H.S., Killelea, B.K., Evans, S.B., Growing use of mastectomy for ductal carcinoma-in situ of the breast among young women in the United States (2015) Ann. Surg. Oncol., 22 (July (7)), pp. 2378-2386; Shah, C., Vicini, F.A., Berry, S., Julian, T.B., Wilkinson, J.B., Shaitelman, S.F., Khan, A., Goldstein, N., Ductal carcinoma in situ of the breast: evaluating the role of radiation therapy in the management and attempts to identify low-risk patients (2015) Am. J. Clin. Oncol., 38 (October (5)), pp. 526-533; Siegel, R.L., Miller, K.D., Jemal, A., Cancer statistics, 2018 (2018) CA Cancer J. Clin., 68 (Jane (1)), pp. 7-30; Solin, L.J., Gray, R., Hughes, L.L., Wood, W.C., Lowen, M.A., Badve, S.S., Baehner, F.L., Davidson, N.E., Surgical excision without radiation for ductal carcinoma in situ of the breast: 12-year results from the ECOG-ACRIN E5194 study (2015) J. Clin. Oncol., 33 (November (33)), pp. 3938-3944; Staley, H., McCallum, I., Bruce, J., Postoperative tamoxifen for ductal carcinoma in situ: cochrane systematic review and meta-analysis (2014) Breast, 23 (October (5)), pp. 546-551; START Trialists’ Group, Bentzen, S.M., Agrawal, R.K., Aird, E.G., Barrett, J.M., Barrett-Lee, P.J., Bentzen, S.M., Yarnold, J.R., The UK Standardisation of Breast Radiotherapy (START) Trial B of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial (2008) Lancet, 371 (March (9618)), pp. 1098-1107; START Trialists’ Group, Bentzen, S.M., Agrawal, R.K., Aird, E.G., Barrett, J.M., Barrett-Lee, P.J., Bliss, J.M., Yarnold, J.R., The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomized trial (2008) Lancet Oncol., 9 (April (4)), pp. 331-341; Strach, M.C., Prasanna, T., Kirova, Y.M., Alran, S., O'Toole, S., Beith, J.M., Poortmans, P., Carroll, S., Optimise not compromise: the importance of a multidisciplinary breast cancer patient pathway in the era of oncoplastic and reconstructive surgery (2019) Crit. Rev. Oncol. Hematol., 134 (February), pp. 10-21; Timbrell, S., Al-Himdani, S., Shaw, O., Tan, K., Morris, J., Bundred, N., Comparison of local recurrence after simple and skin-sparing mastectomy performed in patients with ductal carcinoma in situ (2017) Ann. Surg. Oncol., 24 (April (4)), pp. 1071-1076; Tsang, Y., Haviland, J., Venables, K., Yarnold, J., FTM Group, The impact of dose heterogeneity on late normal tissue complication risk after hypofractionated whole breast radiotherapy (2012) Radiother. Oncol., 104, pp. 143-147; Vargas, C., Kestin, L., Go, N., Krauss, D., Chen, P., Goldstein, N., Martinez, A., Vicini, F.A., Factors associated with local recurrence and cause-specific survival in patients with ductal carcinoma in situ of the breast treated with breast-conserving therapy or mastectomy (2005) Int. J. Radiat. Oncol. Biol. Phys., 63 (December (5)), pp. 1514-1521; Wai, E.S., Lesperance, M.L., Alexander, C.S., Truong, P.T., Culp, M., Moccia, P., Lindquist, J.F., Olivotto, I.A., Effect of radiotherapy boost and hypofractionation on outcomes in ductal carcinoma in situ (2011) Cancer, 117 (January (1)), pp. 54-62; Wapnir, I.L., Dignam, J.J., Fisher, B., Mamounas, E.P., Anderson, S.J., Julian, T.B., Land, S.R., Wolmark, N., Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS (2011) J. Natl. Cancer Inst., 103 (March (6)), pp. 478-488; Wärnberg, F., Garmo, H., Emdin, S., Hedberg, V., Adwall, L., Sandelin, K., Ringberg, A., Holmberg, L., Effect of radiotherapy after breast-conserving surgery for ductal carcinoma in situ: 20 years follow-up in the randomized SweDCIS Trial (2014) J. Clin. Oncol., 32 (November (32)), pp. 3613-3618; Whelan, T.J., Pignol, J.P., Levine, M.N., Julian, J.A., MacKenzie, R., Parpia, S., Shelley, W., Freeman, C., Long-term results of hypofractionated radiation therapy for breast cancer (2010) N. Engl. J. Med., 362 (February (6)), pp. 513-520; Williamson, D., Dinniwell, R., Fung, S., Pintilie, M., Done, S.J., Fyles, A.W., Local control with conventional and hypofractionated adjuvant radiotherapy after breast-conserving surgery for ductal carcinoma in-situ (2010) Radiother. Oncol., 95 (June (3)), pp. 317-320. , doi: 0.1016/j.radonc.2010.03.021; Zhao, H., Hei, N., Wu, Y., Chan, W., Lei, X., Cameron, C., Chang, S., Giordano, S.H., Initiation of and adherence to tamoxifen and aromatase inhibitor therapy among elderly women with ductal carcinoma in situ (2017) Cancer, 123 (May (6)), pp. 940-947
PY - 2019
Y1 - 2019
N2 - Background: Risk factors for local recurrence after mastectomy in ductal carcinoma in situ (DCIS) emerged as a grey area during the second “Assisi Think Tank Meeting” (ATTM) on Breast Cancer. Aim: To review practice patterns of post-mastectomy radiation therapy (PMRT) in DCIS, identify risk factors for recurrence and select suitable candidates for PMRT. Methods: A questionnaire concerning DCIS management, focusing on PMRT, was distributed online via SurveyMonkey. Results: 142 responses were received from 15 countries. The majority worked in academic institutions, had 5–20 years work-experience and irradiated 5 cm, skin- or nipple- sparing mastectomy. Moderate hypofractionation was the most common schedule, except after immediate breast reconstruction (57% conventional fractionation). Conclusions: The present survey highlighted risk factors for PMRT administration, which should be further evaluated. © 2019 Elsevier B.V.
AB - Background: Risk factors for local recurrence after mastectomy in ductal carcinoma in situ (DCIS) emerged as a grey area during the second “Assisi Think Tank Meeting” (ATTM) on Breast Cancer. Aim: To review practice patterns of post-mastectomy radiation therapy (PMRT) in DCIS, identify risk factors for recurrence and select suitable candidates for PMRT. Methods: A questionnaire concerning DCIS management, focusing on PMRT, was distributed online via SurveyMonkey. Results: 142 responses were received from 15 countries. The majority worked in academic institutions, had 5–20 years work-experience and irradiated 5 cm, skin- or nipple- sparing mastectomy. Moderate hypofractionation was the most common schedule, except after immediate breast reconstruction (57% conventional fractionation). Conclusions: The present survey highlighted risk factors for PMRT administration, which should be further evaluated. © 2019 Elsevier B.V.
KW - Breast cancer
KW - Ductal carcinoma in situ
KW - Hypofractionation
KW - Post-mastectomy radiotherapy
KW - Survey
KW - estrogen receptor
KW - Ki 67 antigen
KW - progesterone receptor
KW - tamoxifen
KW - age
KW - breast radiotherapy
KW - breast reconstruction
KW - cancer grading
KW - human
KW - hypofractionated radiotherapy
KW - immunohistochemistry
KW - intensity modulated radiation therapy
KW - intraductal carcinoma
KW - mastectomy
KW - nipple sparing mastectomy
KW - postmastectomy radiation therapy
KW - radiation oncologist
KW - Review
KW - skin sparing mastectomy
KW - surgical margin
KW - surgical technique
KW - tomotherapy
KW - tumor volume
KW - adjuvant radiotherapy
KW - breast tumor
KW - female
KW - middle aged
KW - prevention and control
KW - procedures
KW - questionnaire
KW - radiation oncology
KW - risk factor
KW - tumor recurrence
KW - Breast Neoplasms
KW - Carcinoma, Intraductal, Noninfiltrating
KW - Dose Fractionation, Radiation
KW - Female
KW - Humans
KW - Mastectomy
KW - Middle Aged
KW - Neoplasm Recurrence, Local
KW - Radiation Oncology
KW - Radiotherapy, Adjuvant
KW - Risk Factors
KW - Surveys and Questionnaires
U2 - 10.1016/j.critrevonc.2019.04.016
DO - 10.1016/j.critrevonc.2019.04.016
M3 - Article
VL - 138
SP - 207
EP - 213
JO - Crit. Rev. Oncol. Hematol.
JF - Crit. Rev. Oncol. Hematol.
SN - 1879-0461
ER -